Anticoagulation management in clinical practice: Preventing stroke in patients with atrial fibrillation

Heart and Lung: Journal of Acute and Critical Care

Volumn 41, Issue 2, 2012, Pages 146-156

  Hickey, Kathleen ^a  

^a Columbia University ^*  (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cardioversion; Risk stratification; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ANTICOAGULANT AGENT; APIXABAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; FRESH FROZEN PLASMA; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIALYSIS; DISEASE CLASSIFICATION; DRUG ELIMINATION; DRUG HALF LIFE; ERYTHROCYTE CONCENTRATE; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MYOCARDITIS; OVERANTICOAGULATION; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STROKE;

EID: 84857364836     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2011.07.008     Document Type: Review

References (72)

1. Albers G.W., Dalen J.E., Laupacis A., Manning W.J., Petersen P., Singer D.E. Antithrombotic therapy in atrial fibrillation. Chest 2001, 119(Suppl):194S-206S.
2. Finsterer J., Stollberger C. Strategies for primary and secondary stroke prevention in atrial fibrillation. Neth J Med 2008, 66:327-333.
3. Miyasaka Y., Barnes M.E., Gersh B.J., Cha S.S., Bailey K.R., Abhayaratna W.P., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
4. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
5. Caro J.J. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004, 10(Suppl):S451-S461.
6. Savelieva I., Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008, 31:55-62.
7. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
9. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
10. Hart R.G., Pearce L.A., Rothbart R.M., McAnulty J.H., Asinger R.W., Halperin J.L. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000, 35:183-187.
11. Miller P.S., Andersson F.L., Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?. Stroke 2005, 36:360-366.
12. Levy S., Camm A.J., Saksena S., Aliot E., Breithardt G., Crijns H., et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 2003, 5:119-122.
13. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
14. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
15. Hersi A., Wyse D.G. Management of atrial fibrillation. Curr Probl Cardiol 2005, 30:175-233.
16. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137:263-272.
17. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
18. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl):546S-592S.
19. Heart Rhythm Society. Catheter ablation. Available from: Accessed April 7, 2010. http://www.hrsonline.org/patientinfo/treatments/cathabl/index.cfm.
20. Calkins H., Brugada J., Packer D.L., Cappato R., Chen S.A., Crijns H.J., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm 2007, 4:816-861.
21. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001, 104:2118-2150.
22. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
23. DiMarco J.P., Flaker G., Waldo A.L., Corley S.D., Greene H.L., Safford R.E., et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J 2005, 149:650-656.
24. Corley S.D., Epstein A.E., DiMarco J.P., Domanski M.J., Geller N., Greene H.L., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509-1513.
25. Guglin M., Chen R., Curtis A.B. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM Trial. Heart Rhythm 2010, 7:596-601.
26. Mayo Clinic. Ablation vs Drug Therapy for Atrial Fibrillation-Pilot Trial (CABANA). In: Bethesda (MD): National Library of Medicine (US). Available from: Identifier:NCT00578617. Accessed February 3, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00911508?term=CABANA&rank=1NLM.
27. Deutsches Herzzentrum Muenchen. Cardioversion vs. catheter ablation for resistant atrial fibrillation. In: Bethesda (MD): National Library of Medicine (US). Available from: Identifier:NCT00196209. Accessed December 17, 2009. http://clinicaltrials.gov/ct2/show/NCT00196209?term=NCT00196209&rank=1NLM.
28. Ezekowitz M.D., Bridgers S.L., James K.E., Carliner N.H., Colling C.L., Gornick C.C., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406-1412.
29. Edvardsson N., Juul-Moller S., Omblus R., Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003, 254:95-101.
30. Perez-Gomez F., Alegria E., Berjon J., Iriarte J.A., Zumalde J., Salvador A., et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004, 44:1557-1566.
31. 2 score = 1. Thromb Haemost 2010, 103:833-840.
32. Rockson S.G., Albers G.W. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004, 43:929-935.
33. Colonna P., Sorino M., de Luca L., Bovenzi F., de Luca I. Antithrombotic therapy in atrial fibrillation: beyond the AFFIRM Study. J Cardiovasc Med (Hagerstown) 2006, 7:505-513.
34. Holbrook A.M., Pereira J.A., Labiris R., McDonald H., Douketis J.D., Crowther M., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
35. European Atrial Fibrillation Trial Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262.
36. Petersen P., Boysen G., Godtfredsen J., Andersen E.D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989, 1:175-179.
37. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84:527-539.
38. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505-1511.
39. Le D.T., Weibert R.T., Sevilla B.K., Donnelly K.J., Rapaport S.I. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994, 120:552-558.
40. United States Food and Drug Administration. Coumadin prescribing information: 2010. Available at: Accessed April 25, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf.
41. White H.D., Gruber M., Feyzi J., Kaatz S., Tse H.F., Husted S., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
42. Douketis J.D., Berger P.B., Dunn A.S., Jaffer A.K., Spyropoulos A.C., Becker R.C., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl):299S-339S.
43. Brass L.M., Krumholz H.M., Scinto J.M., Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28:2382-2389.
44. Albers G.W., Yim J.M., Belew K.M., Bittar N., Hattemer C.R., Phillips B.G., et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996, 156:2311-2316.
45. Aberegg S.K., Arkes H., Terry P.B. Failure to adopt beneficial therapies caused by bias in medical evidence evaluation. Med Decis Making 2006, 26:575-582.
46. Monette J., Gurwitz J.H., Rochon P.A., Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997, 45:1060-1065.
47. McCrory D.C., Matchar D.B., Samsa G., Sanders L.L., Pritchett E.L. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995, 155:277-281.
48. Kutner M., Nixon G., Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991, 151:1950-1953.
49. Beyth R.J., Landefeld C.S. Outcomes of warfarin therapy: lessons from the real world. Mayo Clin Proc 1995, 70:806-808.
50. Chang H.J., Bell J.R., Deroo D.B., Kirk J.W., Wasson J.H. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990, 150:83-86.
51. Fitzmaurice D.A., Blann A.D., Lip G.Y. Bleeding risks of antithrombotic therapy. Br Med J 2002, 325:828-831.
52. Strong S.H., Halperin J.L. Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies. Geriatrics 2007, 62:22-27.
53. Somerfield J., Barber P.A., Anderson N.E., Kumar A., Spriggs D., Charleston A., et al. Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapy. Stroke 2006, 37:1217-1220.
54. Lane D.A., Lip G.Y. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008, 39:7-9.
55. Mant J., Hobbs F.D., Fletcher K., Roalfe A., Fitzmaurice D., Lip G.Y., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
56. Lane D., Lip G.Y. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age Ageing 2005, 34:1-3.
57. Fuller R., Dudley N., Blacktop J. Avoidance hierarchies and preferences for anticoagulation: semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin. Age Ageing 2004, 33:608-611.
58. Waterman A.D., Milligan P.E., Bayer L., Banet G.A., Gatchel S.K., Gage B.F. Effect of warfarin nonadherence on control of the international normalized ratio. Am J Health Syst Pharm 2004, 61:1258-1264.
59. Sobieraj-Teague M., O'Donnell M., Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009, 35:515-524.
60. Boehringer-Ingelheim. Pradaxa (dabigatran etexilate): prescribing information. Available from: Accessed October 25, 2010. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
61. Bates S.M., Weitz J.I. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000, 12(Suppl F):27F-32F.
62. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
63. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY Trial. N Engl J Med 2010, 363:1875-1876.
64. van Ryn J., Lintzenburger T., Waterman A., Canada K., Hauel N.H., Sarko C., et al. Dabigatran anticoagulant activity is neutralized by antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011, 57:1130.
65. Nagarakanti R., Ezekowitz M.D., Oldgren J., Yang S., Chernick M., Aikens T.H., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011, 123:131-136.
66. Ma Q. Development of oral anticoagulants. Br J Clin Pharmacol 2007, 64:263-265.
67. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, [Epub ahead of print].
68. Turpie A.G. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008, 29:155-165.
69. Wann L.S., Curtis A.B., Ellenbogen K.A., Estes N.A., Ezekowitz M.D., Jackman W.M., et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:1144-1150.
70. Crowther M.A., Ageno W., Garcia D., Wang L., Witt D.M., Clark N.P., et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009, 150:293-300.
71. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348:423-428.
72. Salem DN, O'Gara PT, Madias C, Pauker SG. American College of Chest Physicians. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:593S-629S.